Project Grant R01CA308063
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $566K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11794, USA
Similar Awards
- The National Cancer Institute awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $532,553 under Project Grant R01CA315976 on July 1, 2026, to investigate temozolomide-induced DNA damage repair in glioblastoma cells, with particular focus on how transcription-coupled nucleotide excision repair (TC-NER) pathways resolve alkylation damage and contribute to drug resistance. The research examines how temozolomide adducts arrest RNA polymerase II...
- The National Cancer Institute awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $223,938 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support basic research on the mechanisms of cGAS activation in innate immune response to cytosolic double-stranded DNA. The research elucidates how MRE11, a DNA repair protein, mediates cGAS release from chromatin and facilitates cGAS-STING pathway activation in...
- The National Cancer Institute of the Department of Health and Human Services awarded The Research Foundation for the State University of New York $662,962 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop an engineered glioblastoma cerebral organoid (GLICO) model system that enables spatially controlled manipulation of tissue mechanics to study how mechanical stress at the GBM-brain interface shapes metabolic heterogeneity and drives invasion and...
- The National Cancer Institute, under the Department of Health and Human Services, awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $498,775 under Cancer Biology Research (CFDA 93.396) on July 1, 2026. The award funds investigation of targetable mechanisms driving altered cell states in castration-resistant prostate cancer. The project dissects the emergence of a specific cellular subtype in early-stage prostate cancer capable of...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $683,256 on May 22, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a human-mouse platform for patient stratification and therapeutic target discovery in glioblastoma. The recipient will integrate single-cell RNA-sequencing data from 199 glioblastoma patients with spatial transcriptomics technologies to dissect tumor microenvironment cell composition, spatial tissue organization,...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026. The recipient will conduct research into epigenetic regulation of glioblastoma stem-like cells, specifically exploring how the arginine methyltransferase CARM1 controls NGFR and NTRK signaling pathways. The work encompasses two primary aims: testing...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute awarded Duke University $726,421 under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 19, 2026, to investigate epigenetic mechanisms of adaptive plasticity in glioblastoma. The research develops and validates methods for predicting cell state–specific vulnerabilities based on epigenetic data in glioblastoma tumors, characterizes adaptive plasticity–induced vulnerabilities during therapy using heterogeneous tumor models, and validates...